What is the appropriate first-line therapy for acute uncomplicated cystitis in a non‑pregnant adult woman without recent antibiotic use or known resistance?

First-Line Therapy for Acute Uncomplicated Cystitis

Nitrofurantoin monohydrate/macrocrystals 100 mg orally twice daily for 5 days is the preferred first-line treatment for acute uncomplicated cystitis in non-pregnant adult women without recent antibiotic use or known resistance. 1, 2

Primary Recommendation

• Nitrofurantoin achieves 88–93% clinical cure and 81–92% microbiological eradication rates while maintaining worldwide resistance rates below 1%. 1, 2
• This agent causes minimal disruption to intestinal flora compared with fluoroquinolones and broad-spectrum agents, thereby reducing the risk of Clostridioides difficile infection and other collateral antimicrobial damage. 1, 2
• The full 5-day course is required for optimal efficacy; shorter durations are inadequate. 2
• Nitrofurantoin should be avoided when estimated glomerular filtration rate (eGFR) is <30 mL/min/1.73 m² because therapeutic urinary concentrations cannot be achieved. 1, 2

Alternative First-Line Options

Fosfomycin Trometamol

• A single 3-gram oral dose provides approximately 91% clinical cure with therapeutic urinary concentrations maintained for 24–48 hours. 1, 2
• Fosfomycin offers the advantage of single-dose convenience, which maximizes adherence, and demonstrates low resistance rates (2.6% in initial E. coli infections). 1
• This agent should not be used for suspected pyelonephritis or upper urinary tract infections due to insufficient tissue penetration. 1, 2
• Microbiological eradication rates (78–80%) are modestly lower than nitrofurantoin, though overall clinical efficacy remains comparable. 1, 2

Trimethoprim-Sulfamethoxazole (TMP-SMX)

• TMP-SMX 160/800 mg orally twice daily for 3 days achieves 93% clinical cure and 94% microbiological eradication when the pathogen is susceptible. 1, 2
• This regimen should be prescribed only when both of the following criteria are met: (1) local E. coli resistance is documented to be <20%, and (2) the patient has not received TMP-SMX in the preceding 3 months. 1, 2
• When resistance exceeds 20%, clinical cure rates drop to 41–54%, indicating unacceptably high treatment failure. 1, 2
• Many regions now report TMP-SMX resistance >20%; verification of current local antibiogram data is mandatory before empiric use. 1

Treatment Selection Algorithm

1. Assess renal function: If eGFR ≥30 mL/min/1.73 m² → prescribe nitrofurantoin 100 mg twice daily for 5 days. 1, 2

2. If nitrofurantoin is contraindicated (eGFR <30 mL/min/1.73 m² or suspected pyelonephritis) → prescribe fosfomycin 3 g single dose. 1, 2

3. If both nitrofurantoin and fosfomycin are unsuitable: Verify local E. coli TMP-SMX resistance is <20% and confirm no TMP-SMX use in prior 3 months → prescribe TMP-SMX 160/800 mg twice daily for 3 days. 1, 2

4. If all first-line agents are contraindicated: Reserve fluoroquinolones or beta-lactams for culture-proven resistance only (see below). 1, 2

Reserve (Second-Line) Agents – Use Only When First-Line Options Fail

Fluoroquinolones

• Ciprofloxacin 250 mg twice daily or levofloxacin 250 mg once daily for 3 days should be reserved exclusively for culture-proven resistant organisms or documented failure of first-line therapy. 1, 2
• The 2016 FDA advisory recommends against fluoroquinolone use for uncomplicated UTIs because serious adverse effects (tendon rupture, peripheral neuropathy, CNS toxicity) outweigh benefits. 1
• Global fluoroquinolone resistance is rising, with some regions reporting >10% resistance among uropathogens. 1
• Empiric fluoroquinolones should not be used as first-line therapy despite high efficacy (~95% clinical cure) to preserve their utility for complicated infections and prevent resistance development. 1, 2

Beta-Lactam Agents

• Amoxicillin-clavulanate, cefdinir, cefaclor, or cefpodoxime given for 3–7 days achieve only 89% clinical cure and 82% microbiological eradication, which is significantly inferior to first-line agents. 1, 2
• Beta-lactams are associated with higher adverse-event rates and more rapid UTI recurrence due to disturbance of protective peri-urethral and vaginal microbiota. 1
• These agents should be used only when all first-line options are contraindicated. 1, 2
• Amoxicillin or ampicillin alone should never be used empirically because worldwide E. coli resistance exceeds 55–67%. 1, 2

Diagnostic Considerations

• Routine urine culture is not required for otherwise healthy women presenting with typical lower-tract symptoms (dysuria, frequency, urgency) without systemic signs. 1, 2
• Obtain urine culture and susceptibility testing when any of the following occur: persistent symptoms after completing therapy, recurrence within 2–4 weeks, fever >38°C, flank pain or costovertebral-angle tenderness, atypical presentation, or history of recurrent infections. 1, 2

Management of Treatment Failure

• If symptoms persist after 2–3 days of therapy or recur within 2 weeks, obtain a urine culture immediately and switch to a different antibiotic class for a full 7-day course. 1, 2
• Assume the original pathogen is resistant to the previously used agent; do not repeat the same antibiotic or class. 1
• Reserve fluoroquinolones only for culture-proven resistance to all first-line agents. 1, 2

Critical Pitfalls to Avoid

• Do not prescribe TMP-SMX empirically without confirming that local E. coli resistance is <20%; treatment failure rates rise sharply above this threshold. 1, 2
• Do not treat asymptomatic bacteriuria in non-pregnant, non-catheterized women, as this promotes resistance without clinical benefit. 1
• Do not use nitrofurantoin for suspected pyelonephritis (fever, flank pain) or when eGFR <30 mL/min/1.73 m². 1, 2
• Do not use fosfomycin for suspected upper-tract infection due to inadequate tissue penetration. 1, 2
• Do not shorten nitrofurantoin therapy to <5 days; the full course is required for optimal efficacy. 2
• Do not use empiric fluoroquinolones as first-line therapy despite high efficacy, to preserve these agents for serious infections. 1, 2